Skip to main content
AKTX
NASDAQ Life Sciences

Akari Therapeutics Q2 2026: Wider Loss, $7.7M Cash, Phase 1 Trial Set for Mid-2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$7
Mkt Cap
$8.218M
52W Low
$3.015
52W High
$49.6
52W Position info
132% above low
Off High info
86% below high
Rel. Volume
Market data snapshot near publication time

AKTX has more than doubled off its 52-week low of $3.015.

Summary

Akari Therapeutics reported a wider Q2 2026 net loss of $4.8 million and cash of $7.7 million, while highlighting progress toward a Phase 1 trial for AKTX-101 in mid-2027 and a new ADC collaboration.


Key Events · Earnings and Guidance · AKTX

  • Q2 Net Loss Widens

    Net loss was $4.8 million for Q2 2026, compared with $1.9 million in Q2 2025, driven by higher R&D spending.

  • Cash Position

    Cash totaled $7.7 million as of June 30, 2026, up from $5.2 million at year-end 2025 after raising $8.6 million in gross proceeds.

  • Phase 1 Trial Planned

    Company remains on track to initiate a Phase 1 clinical trial for AKTX-101 in mid-2027.

  • Whitehawk Collaboration

    Announced a research collaboration with Whitehawk Therapeutics to evaluate dual-payload ADCs combining PH1 and topoisomerase I platforms.


Analysis · AKTX · Life Sciences

A net loss of $4.8 million for Q2 2026—more than double the $1.9 million loss a year earlier—reflects a tripling of R&D spend to $2.1 million as Akari Therapeutics advances AKTX-101 toward clinical trials. Cash stands at $7.7 million after raising $8.6 million in gross proceeds during the quarter, providing runway but still tight for a company with a going-concern warning. The company also announced a strategic collaboration with Whitehawk Therapeutics and positive preclinical data at ASCO, but the near-term focus remains on capital needs and the mid-2027 Phase 1 timeline.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3715 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AKTX was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $3.02 to $49.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AKTX - Latest Insights

AKTX
Nov 12, 2026, 5:21 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.67
Real-time Price: $7.00 info
Change: +$0.330 (+5%) info
Market Cap: $15.539M info
AKTX
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $6.51
Real-time Price: $7.00 info
Change: +$0.490 (+8%) info
Market Cap: $15.539M info
AKTX
Nov 12, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $6.51
Real-time Price: $7.00 info
Change: +$0.490 (+8%) info
Market Cap: $15.539M info
AKTX
Aug 18, 2026, 8:56 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.79
Real-time Price: $7.00 info
Change: -$0.790 (-10%) info
Market Cap: $15.539M info
AKTX
Aug 13, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $7.00
Real-time Price: $7.00 info
Change: $0 (0%) info
Market Cap: $15.539M info